Related Experiment Video
Updated: Jan 3, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Calcium-sensing receptor gene (CASR) polymorphisms and CASR transcript level concerning dyslipidemia in hemodialysis
Alicja E Grzegorzewska1, Bartosz A Frycz2, Monika Świderska3
1Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznań, Poland. alicja_grzegorzewska@yahoo.com.
Insights
Single nucleotide polymorphisms (SNPs) in the CASR gene are linked to dyslipidemia in hemodialysis patients. These CASR SNPs did not show epistatic interactions with other genes but correlated with gene transcript levels.
Area of Science:
- Genetics
- Nephrology
- Cardiovascular Disease
Background:
- Limited data exists on the association between the calcium-sensing receptor (CASR) gene and dyslipidemia.
- Hemodialysis (HD) patients represent a population with a high prevalence of dyslipidemia and cardiovascular risk.
Purpose of the Study:
- To investigate the association of CASR single nucleotide polymorphisms (SNPs) rs7652589 and rs1801725 with dyslipidemia in HD patients.
- To explore potential epistatic interactions between CASR SNPs and SNPs in energy homeostasis-associated genes (ENHO), retinoid X receptor alpha (RXRA), and liver X receptor alpha (LXRA).
Main Methods:
- Genotyping of CASR SNPs rs7652589 and rs1801725 in 1208 HD subjects.
- Dyslipidemia diagnosis using K/DOQI criteria and atherogenic index.
- Measurement of relative transcript levels of CASR, ENHO, RXRA, and LXRA in peripheral blood mononuclear cells.
- Analysis of genetic associations, linkage disequilibrium, haplotypes, and epistatic interactions using logistic regression and PLINK software.
Main Results:
- CASR rs7652589 was associated with an increased probability of atherogenic dyslipidemia, primarily due to elevated triglyceride levels (OR 1.4, P=0.026).
- CASR rs1801725 variant allele was linked to a decreased probability of dyslipidemia characterized by high non-HDL-cholesterol and triglyceride levels (OR 0.6, P=0.012).
- No significant epistatic interactions were found between CASR SNPs and RXRA, LXRA, or ENHO SNPs regarding dyslipidemia. CASR transcript levels showed positive correlations with RXRA, LXRA, and ENHO transcript levels.
Conclusions:
- CASR polymorphisms rs7652589 and rs1801725 are associated with dyslipidemia in hemodialysis patients.
- CASR gene expression correlates with RXRA, LXRA, and ENHO at the transcript level in this cohort.
- Further research is warranted to explore other CASR SNPs and their contribution to dyslipidemia in HD patients.
Background:
There is scarce data on CASR associations with dyslipidemia. We investigated in hemodialysis (HD) patients whether CASR single nucleotide polymorphisms (SNPs) rs7652589 and rs1801725 have associations with dyslipidemia and show epistatic interactions with SNPs of the energy homeostasis-associated gene (ENHO), retinoid X receptor α gene (RXRA), and liver X receptor α gene (LXRA).
Methods:
The study included 1208 HD subjects. For diagnosis of dyslipidemia, both K/DOQI criteria and atherogenic index ≥3.8 were used. CASR rs1801725 was genotyped by TaqMan SNP Genotyping Assay, other SNPs - by high-resolution melting curve analysis or polymerase chain reaction-restriction fragment length polymorphism, as appropriate. Relative transcript levels of CASR, ENHO, RXRA, and LXRA were measured in peripheral blood mononuclear cells. The occurrence of dyslipidemic phenotypes concerning tested polymorphisms was compared using models of inheritance. Haplotypes were estimated using the Haploview 4.2 software. Epistatic interactions between tested SNPs were analyzed using the logistic regression and epistasis option in the PLINK software.
Results:
Rs7652589 indicated a greater probability of atherogenic dyslipidemia in the dominant inheritance model (OR 1.4, 95%CI 1.0-2.0, P = 0.026), principally because of increased triglyceride (TG) levels. The rs1801725 variant allele was associated with a decreased probability of dyslipidemia characterized by non-HDL-cholesterol ≥130 mg/dL and TG ≥200 mg/dL (OR 0.6, 0.4-0.9, P = 0.012). There were no epistatic interactions between CASR and RXRA, LXRA, and ENHO regarding dyslipidemia. Both rs7652589 and rs1801725 SNPs were not in linkage disequilibrium (D' = 0.091, r2 = 0.003 for the entire HD group) and their haplotypes did not correlate with dyslipidemia. Relative CASR transcript was lower at a borderline significance level in patients harboring the rs1801725 variant allele compared with homozygotes of the major allele (0.20, 0.06-7.80 vs. 0.43, 0.04-5.06, P = 0.058). CASR transcript correlated positively with RXRA transcript (adjusted P = 0.001), LXRA transcript (adjusted P = 0.0009), ENHO transcript (borderline significance, adjusted P = 0.055), dry body weight (adjusted P = 0.035), and renal replacement therapy duration (adjusted P = 0.013).
Conclusions:
CASR polymorphisms (rs7652589, rs1801725) are associated with dyslipidemia in HD patients. CASR correlates with RXRA, LXRA, and ENHO at the transcript level. Further investigations may elucidate whether other CASR SNPs contribute to associations shown in this study.
More Related Videos
13:40Live Cell Calcium Imaging Combined with siRNA Mediated Gene Silencing Identifies Ca2+ Leak Channels in the ER Membrane and their Regulatory Mechanisms
Published on: July 7, 2011
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology